Philip Morris International (PM) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
19 Jan, 2026Executive summary
Delivered record Q3 2024 results with double-digit organic growth in revenue, operating income, and EPS, driven by strong performance across all business segments, especially smoke-free products and ZYN nicotine pouches.
Raised full-year 2024 guidance for volume, organic sales growth, operating income, and EPS, reflecting broad-based acceleration in IQOS, ZYN, and combustibles.
Net revenues for the nine months ended September 30, 2024, increased 7.8% to $28.2B, with smoke-free products accounting for 38.2% of net revenues.
Operating income rose 17.0% to $10.1B, and net earnings attributable to PMI surged 35.9% to $7.6B, with diluted EPS up 35.5% to $4.89.
Key events included a $198M Vectura impairment, full U.S. IQOS rights acquisition, and ongoing regulatory, litigation, and geopolitical risks.
Financial highlights
Q3 2024 organic net revenues grew 11.6% year-over-year to $9.9B, with operating income up 13.8% and adjusted diluted EPS up 14.4% to $1.91, or 18% excluding currency.
Gross profit increased 13.0% overall, with smoke-free gross profit up 20.2% and combustibles up 8.7%.
Nine-month net revenues up 7.8% to $28.2B; net earnings attributable to PMI up 35.9% to $7.6B.
Net cash from operating activities reached $8.2B for nine months, up from $5.9B in 2023.
Dividend increased 3.8% to $1.35 per share quarterly ($5.40 annualized).
Outlook and guidance
Raised 2024 shipment volume growth outlook to 2–3%, with adjusted IMS HTU volume growth of around 13%.
Organic net revenue growth forecast increased to around 9.5%, with smoke-free net revenue expected to reach nearly $15B.
Adjusted organic operating income growth forecast raised to 14–14.5%; adjusted diluted EPS forecast at $6.45–$6.51, including a $0.40 currency headwind.
Net cash from operating activities for 2024 expected to be approximately $11B; capex of ~$1.4B.
No share repurchases in 2024; net debt/adjusted EBITDA ratio targeted at ~2x by end of 2026.
Latest events from Philip Morris International
- Smoke-free products drive growth, margin expansion, and strong shareholder returns for 2026–28.PM
Consumer Analyst Group of New York Conference (CAGNY) 202618 Feb 2026 - 2025 saw double-digit smoke-free growth, record EPS, and a strong 2026 growth outlook.PM
Q4 20258 Feb 2026 - EPS growth of 13%-15% expected, fueled by smoke-free momentum and margin expansion.PM
Barclays 18th Annual Global Consumer Staples Conference 20253 Feb 2026 - Record H1 smoke-free growth drove raised 2024 guidance despite regulatory and currency headwinds.PM
Q2 20243 Feb 2026 - Smoke-free product growth and raised EPS guidance highlight a strong 2024 outlook.PM
21st Annual dbAccess Global Consumer Conference31 Jan 2026 - Strong NGP-driven growth, robust margins, and disciplined capital allocation define the outlook.PM
Barclays Global Consumer Staples Conference 202422 Jan 2026 - Double-digit growth in 2024 driven by smoke-free products, with strong 2025 outlook.PM
Q4 20248 Jan 2026 - Q1 2025 saw double-digit growth in net revenues and EPS, led by smoke-free products.PM
Q1 202519 Dec 2025 - Smoke-free products and premium brands fuel growth, margin gains, and global expansion.PM
Morgan Stanley Global Consumer & Retail Conference 20252 Dec 2025